Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B trial

MLA

H. T. Mouridsen, et al. “Tamoxifen in High-Risk Premenopausal Women with Primary Breast Cancer Receiving Adjuvant Chemotherapy. Report from the Danish Breast Cancer Co-Operative Group DBCG 82B Trial.” European Journal of Cancer, vol. 35, Nov. 1999, pp. 1659–66. EBSCOhost, https://doi.org/10.1016/s0959-8049(99)00141-0.

APA

H. T. Mouridsen, Marie Overgaard, Carsten Rose, M.B. Jensen, Jørn Andersen, Mogens Kjaer, S. Cold, Martin Andersson, Bent Ejlertsen, Claus Kamby, & P. Dombernowsky. (1999). Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B trial. European Journal of Cancer, 35, 1659–1666. https://doi.org/10.1016/s0959-8049(99)00141-0

Chicago

H. T. Mouridsen, Marie Overgaard, Carsten Rose, M.B. Jensen, Jørn Andersen, Mogens Kjaer, S. Cold, et al. 1999. “Tamoxifen in High-Risk Premenopausal Women with Primary Breast Cancer Receiving Adjuvant Chemotherapy. Report from the Danish Breast Cancer Co-Operative Group DBCG 82B Trial.” European Journal of Cancer 35 (November): 1659–66. doi:10.1016/s0959-8049(99)00141-0.